Structure-based design of potent and selective 2-(quinazolin-2-yl)phenol inhibitors of checkpoint kinase 2.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2011-01-27

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/jm101150bPMID 21186793
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors.

  2011cited by this paper
• Design and evaluation of 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines as inhibitors of checkpoint and other kinases.

  2010cited by this paper
• Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2.

  2010cited by this paper
• Probing the Probes: Fitness Factors For Small Molecule Tools

  2010cited by this paper
• A Novel Small-Molecule Inhibitor of Protein Kinase D Blocks Pancreatic Cancer Growth In vitro and In vivo

  2010cited by this paper
• Taking the time to make important decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage response.

  2009cited by this paper
• Cellular Inhibition of Checkpoint Kinase 2 (Chk2) and Potentiation of Camptothecins and Radiation by the Novel Chk2 Inhibitor PV1019 [7-Nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]

  2009cited by this paper
• Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2.

  2009cited by this paper
• Modes of p53 regulation.

  2009cited by this paper
• p53-based cancer therapies: Is defective p53 the Achilles heel of the tumor?

  2007cited by this paper
• Identification of a bis-guanylhydrazone ( NSC 109555 ) as a novel chemotype for inhibition of Chk 2 kinase

  2007cited by this paper
• CHK2 kinase: cancer susceptibility and cancer therapy – two sides of the same coin?

  2007cited by this paper
• Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2

  2007cited by this paper
• Identification of novel, selective and potent Chk2 inhibitors.

  2007cited by this paper
• Identification of a Bis-guanylhydrazone [4,4′-Diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555] as a Novel Chemotype for Inhibition of Chk2 Kinase

  2007cited by this paper
• Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.

  2007cited by this paper
• Gini coefficient: a new way to express selectivity of kinase inhibitors against a family of kinases.

  2007cited by this paper
• Chk2 Molecular Interaction Map and Rationale for Chk2 Inhibitors

  2006cited by this paper
• Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.

  2006cited by this paper
• Novel non-benzimidazole chk2 kinase inhibitors.

  2006cited by this paper
• Trans‐activation of the DNA‐damage signalling protein kinase Chk2 by T‐loop exchange

  2006cited by this paper
• Chk 2 Molecular InteractionMap and Rationale for Chk 2 Inhibitors

  2006cited by this paper
• Glycosylated foldamers to probe the carbohydrate-carbohydrate interaction.

  2006cited by this paper
• Medicinal chemistry of hERG optimizations: Highlights and hang-ups.

  2006cited by this paper
• Targeting chk2 kinase: molecular interaction maps and therapeutic rationale.

  2005cited by this paper
• Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles.

  2005cited by this paper
• Quinazolines, useful as modulators of ion channels

  2004cited by this paper
• Cell-cycle checkpoints and cancer

  2004cited by this paper
• Developments in the CCP4 molecular-graphics project.

  2004cited by this paper
• Autophosphorylation of Checkpoint Kinase 2 at Serine 516 Is Required for Radiation-induced Apoptosis*

  2003cited by this paper
• Optimization of a Higher Throughput Microsomal Stability Screening Assay for Profiling Drug Discovery Candidates

  2003cited by this paper
• Chk1 and Chk2 kinases in checkpoint control and cancer.

  2003cited by this paper
• Regulation of the Chk2 protein kinase by oligomerization-mediated cis- and trans-phosphorylation.

  2003cited by this paper
• Phosphorylation of Threonine 68 Promotes Oligomerization and Autophosphorylation of the Chk2 Protein Kinase via the Forkhead-associated Domain*

  2002cited by this paper
• Chk2‐deficient mice exhibit radioresistance and defective p53‐mediated transcription

  2002cited by this paper
• Linking DNA Damage to Cell Cycle Checkpoints

  2002cited by this paper
• The Protein Data Bank

  2000cited by this paper
• Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro.

  2000cited by this paper
• Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation.

  2000cited by this paper
• DNA damage-induced activation of p53 by the checkpoint kinase Chk2.

  2000cited by this paper
• The role of genomic instability in human carcinogenesis.

  1999cited by this paper
• Genetic instabilities in human cancers

  1998cited by this paper
• Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.

  1998cited by this paper
• New colorimetric cytotoxicity assay for anticancer-drug screening.

  1990cited by this paper
• Electronic Reprint Biological Crystallography the Protein Data Bank Biological Crystallography the Protein Data Bank

  year unknowncited by this paper

• Novel imidazolone derivatives as potential dual inhibitors of checkpoint kinases 1 and 2: Design, synthesis, cytotoxicity evaluation, and mechanistic insights.

  2024cites this paper
• DNA damage response revisited: the p53 family and its regulators provide endless cancer therapy opportunities

  2022cites this paper
• Synthesis, biological evaluation and molecular docking studies of novel 1,2,3-triazole-quinazolines as antiproliferative agents displaying ERK inhibitory activity.

  2021cites this paper
• DNA damage checkpoint kinases in cancer

  2020cites this paper
• Evolution of kinase polypharmacology across HSP90 drug discovery

  2020cites this paper
• Autophagy And Apoptosis Specifc Knowledgebases-Guided Systems Pharmacology Drug Research.

  2019cites this paper
• Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.

  2019cites this paper
• Design, Synthesis and Biological Evaluation of Isoxazole-Based CK1 Inhibitors Modified with Chiral Pyrrolidine Scaffolds

  2019cites this paper
• Preclinical Profiles and Contexts for CHK1 and CHK2 Inhibitors

  2018cites this paper
• Part II: New candidates of pyrazole-benzimidazole conjugates as checkpoint kinase 2 (Chk2) inhibitors.

  2018cites this paper
• Part III: Novel checkpoint kinase 2 (Chk2) inhibitors; design, synthesis and biological evaluation of pyrimidine-benzimidazole conjugates.

  2018cites this paper
• Directing the use of DDR kinase inhibitors in cancer treatment

  2017cites this paper
• Objective, Quantitative, Data-Driven Assessment of Chemical Probes

  2017cites this paper
• Synthesis of pyrrolidine-3-carboxylic acid derivatives via asymmetric Michael addition reactions of carboxylate-substituted enones.

  2017cites this paper
• ATM, ATR, CHK1, CHK2 and WEE1 inhibitors in cancer and cancer stem cells.

  2017cites this paper
• Part I: Design, synthesis and biological evaluation of novel pyrazole-benzimidazole conjugates as checkpoint kinase 2 (Chk2) inhibitors with studying their activities alone and in combination with genotoxic drugs.

  2017cites this paper
• Interplay Of Stereochemistry, Conformational Rigidity, And Ease Of Synthesis For 13-Membered Cyclic Peptidomimetics Containing APC Residues.

  2017cites this paper
• Design, synthesis and biological evaluation of 4-anilinoquinazoline derivatives as new c-myc G-quadruplex ligands.

  2016cites this paper
• Synthesis of chalcone incorporated quinazoline derivatives as anticancer agents

  2016cites this paper
• The hunt for antimitotic agents: an overview of structure-based design strategies

  2016cites this paper
• DNA repair targeted therapy: The past or future of cancer treatment?

  2016cites this paper
• DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles’ Heel of Cancer

  2015cites this paper
• Trial Watch: Targeting ATM–CHK2 and ATR–CHK1 pathways for anticancer therapy

  2015cites this paper
• Structure-based design , discovery and development of checkpoint kinase inhibitors as potential anti-cancer therapies

  2014cites this paper
• Protein Kinase D as a Potential Chemotherapeutic Target for Colorectal Cancer

  2014cites this paper
• Novel Design Strategy for Checkpoint Kinase 2 Inhibitors Using Pharmacophore Modeling, Combinatorial Fusion, and Virtual Screening

  2014cites this paper
• Design, synthesis, and evaluation of novel 1-methyl-3-substituted quinazoline-2,4-dione derivatives as antimicrobial agents

  2014cites this paper
• Development of Synthetic Lethality Anticancer Therapeutics

  2014cites this paper
• Investigations on intramolecular 1,3-dipolar cycloadditions for the synthesis of isoxazolo-annulated pyrrolidines, piperidines and azepanes

  2014cites this paper
• Structure-based design and optimization of 2-aminothiazole-4-carboxamide as a new class of CHK1 inhibitors.

  2013cites this paper
• Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies

  2013cites this paper
• Design checkpoint kinase 2 inhibitors by pharmacophore modeling and virtual screening techniques.

  2013cites this paper
• 3D-QSAR Study for Checkpoint Kinase 2 Inhibitors through Pharmacophore Hypotheses

  2013cites this paper
• Radiation Induced DNA Damage, Repair and Therapeutics

  2013cites this paper
• Computer‐Aided Design, Synthesis and Validation of 2‐Phenylquinazolinone Fragments as CDK9 Inhibitors with Anti‐HIV‐1 Tat‐Mediated Transcription Activity

  2013cites this paper
• Fragment-Based Screening Maps Inhibitor Interactions in the ATP-Binding Site of Checkpoint Kinase 2

  2013cites this paper
• Benzimidazole inhibitors of the protein kinase CHK2: Clarification of the binding mode by flexible side chain docking and protein–ligand crystallography

  2012cites this paper
• Synthesis and antitumor activity of novel 2-(1-substituted-piperidin-4-ylamino)quinazolines as antitumor agents.

  2012cites this paper
• Radioprotection by hymenialdisine-derived checkpoint kinase 2 inhibitors.

  2012cites this paper
• Synthesis and evaluation of debromohymenialdisine-derived Chk2 inhibitors.

  2012cites this paper
• Suzuki–Miyaura cross-coupling reaction of aryl and heteroaryl pinacol boronates for the synthesis of 2-substituted pyrimidines

  2012cites this paper
• Polythérapie de composés inhibiteurs de hsp90 avec inhibiteurs de chk

  2012cites this paper
• Checkpoint kinase inhibitors: a patent review (2009 – 2010)

  2011cites this paper
• Anticancer therapy with checkpoint inhibitors: what, where and when?

  2011cites this paper
• Structural characterization of inhibitor complexes with checkpoint kinase 2 (Chk2), a drug target for cancer therapy.

  2011cites this paper
• Palladium-catalyzed intramolecular C(sp2)-H amidination by isonitrile insertion provides direct access to 4-aminoquinazolines from N-arylamidines.

  2011cites this paper
• Synthesis of 4-aminoquinazolines by palladium-catalyzed intramolecular imidoylation of N-(2-bromoaryl)amidines.

  2011cites this paper